Hearing loss and COVID-19: an umbrella review
Introduction COVID-19 can result in an extensive range of extrapulmonary, and neurological signs and symptoms such as olfactory and/or taste dysfunction, and otologic symptoms. The aim of this study was to investigate the hearing loss manifestation from COVID-19. Methods The goal of this umbrella review was to examine hearing loss associated with COVID-19 disease. English literature published until October 15, 2022 in online databases including PubMed, Scopus, Web of Science, and Embase was considered for this purpose. Eligibility of the articles for subsequent data extraction was evaluated in a two-step selection process with consideration to an inclusion/exclusion criterion. This review followed the PRISMA protocol and the Amstar-2 checklist for quality assessment. Results A total of four treatment strategies were used by different studies which included oral corticosteroids, intratympanic corticosteroids, combined oral and intratympanic corticosteroids, and hyperbaric oxygen therapy. Five studies investigated corticosteroid use in the forms of oral or intratympanic injection; four studies reported (complete or partial) hearing improvements after steroid treatment, while one study stated no significant improvement in hearing function. One study reported that oral corticosteroid monotherapy alone was not effective, while vestibular symptoms were ameliorated by a combination of oral prednisone, intratympanic dexamethasone injection, and hydroxychloroquine. Conclusion The findings suggest that despite being one of the rare complications of COVID-19, hearing loss can impact a patient's quality of life. The most common type reported was sensorineural hearing loss, which can be diagnosed with variable techniques..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:280 |
|---|---|
| Enthalten in: |
European archives of oto-rhino-laryngology and head & neck - 280(2023), 8 vom: 24. Apr., Seite 3515-3528 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mehraeen, Esmaeil [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Auditory defect |
|---|
| RVK: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00405-023-07982-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144230099 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144230099 | ||
| 003 | DE-627 | ||
| 005 | 20240118093920.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00405-023-07982-2 |2 doi | |
| 035 | |a (DE-627)OLC2144230099 | ||
| 035 | |a (DE-He213)s00405-023-07982-2-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a XA 26650 |q VZ |2 rvk | ||
| 100 | 1 | |a Mehraeen, Esmaeil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hearing loss and COVID-19: an umbrella review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Introduction COVID-19 can result in an extensive range of extrapulmonary, and neurological signs and symptoms such as olfactory and/or taste dysfunction, and otologic symptoms. The aim of this study was to investigate the hearing loss manifestation from COVID-19. Methods The goal of this umbrella review was to examine hearing loss associated with COVID-19 disease. English literature published until October 15, 2022 in online databases including PubMed, Scopus, Web of Science, and Embase was considered for this purpose. Eligibility of the articles for subsequent data extraction was evaluated in a two-step selection process with consideration to an inclusion/exclusion criterion. This review followed the PRISMA protocol and the Amstar-2 checklist for quality assessment. Results A total of four treatment strategies were used by different studies which included oral corticosteroids, intratympanic corticosteroids, combined oral and intratympanic corticosteroids, and hyperbaric oxygen therapy. Five studies investigated corticosteroid use in the forms of oral or intratympanic injection; four studies reported (complete or partial) hearing improvements after steroid treatment, while one study stated no significant improvement in hearing function. One study reported that oral corticosteroid monotherapy alone was not effective, while vestibular symptoms were ameliorated by a combination of oral prednisone, intratympanic dexamethasone injection, and hydroxychloroquine. Conclusion The findings suggest that despite being one of the rare complications of COVID-19, hearing loss can impact a patient's quality of life. The most common type reported was sensorineural hearing loss, which can be diagnosed with variable techniques. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Auditory defect | |
| 650 | 4 | |a Hearing damage | |
| 650 | 4 | |a Hearing defect | |
| 650 | 4 | |a Hearing loss | |
| 700 | 1 | |a Afzalian, Arian |4 aut | |
| 700 | 1 | |a Afsahi, Amir Masoud |4 aut | |
| 700 | 1 | |a Shahidi, Ramin |4 aut | |
| 700 | 1 | |a Fakhfouri, Amirata |4 aut | |
| 700 | 1 | |a Karimi, Kiana |4 aut | |
| 700 | 1 | |a Varshochi, Sanaz |4 aut | |
| 700 | 1 | |a Habibi, Mohammad Amin |4 aut | |
| 700 | 1 | |a Molla, Ayoob |4 aut | |
| 700 | 1 | |a Dadjou, Ali |4 aut | |
| 700 | 1 | |a Tajabadi, Zohreh |4 aut | |
| 700 | 1 | |a Nasiri, Khadijeh |4 aut | |
| 700 | 1 | |a Seyed Alinaghi, Seyed Ahmad |0 (orcid)0000-0003-4108-2973 |4 aut | |
| 700 | 1 | |a Hackett, Daniel |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European archives of oto-rhino-laryngology and head & neck |d Springer Berlin Heidelberg, 2004 |g 280(2023), 8 vom: 24. Apr., Seite 3515-3528 |w (DE-627)385027494 |w (DE-600)2141531-6 |w (DE-576)111041562 |x 0937-4477 |7 nnns |
| 773 | 1 | 8 | |g volume:280 |g year:2023 |g number:8 |g day:24 |g month:04 |g pages:3515-3528 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00405-023-07982-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4277 | ||
| 936 | r | v | |a XA 26650 |
| 951 | |a AR | ||
| 952 | |d 280 |j 2023 |e 8 |b 24 |c 04 |h 3515-3528 | ||